Withdrawal of Vioxx Brings Exposure to Swiss Medicas Arthritis and Pain Relief Product, O24.

Swiss Medica's arthritis and pain relief product, O24, garners attention with the withdrawal of Vioxx.

October 5, 2004 -- With the withdrawal of Vioxx, Swiss Medica's http://www.024zone.com [arthritis and pain relief] product, 024, gains attention and recognition.

Chief Executive Raghu Kilambi announced, Merck & Cos worldwide withdrawal of its COX-2 medicine, Vioxx, has brought huge opportunity to http://www.swissmedica.com/ [Swiss Medica]. Our http://www.024zone.com/ [pain relief] product that treats arthritis may find a much larger market share, now that thousands of people with arthritis are searching for an alternative to Vioxx. Kilambi went on, The http://www.024zone.com/ [O24 Essential Oil Pain Neutralizer] now celebrates its 10th Anniversary as a safe pain relief alternative to the numerous pills hoping to provide solutions to http://www.024zone.com/ [rheumatoid arthritis] and similar ailments.

In September, the http://www.024zone.com/ [O24 Arthritis Relief Solution] celebrated its 2nd anniversary of having received U.S. Patent Number 6,444,238 entitled A pain relief composition and a method of relieving pain in a human body. The US Patent specifically notes: The pain relief composition of the present invention is formulated from organically derived essential oils. As such, the pain relief composition provides consumers with a technique to reduce the level of pain while not using artificial, man-made compositions. The organically-derived nature of the composition of the present invention has substantial value to those individuals who desire to reduce pain without using artificial, man-made compositions.

Kilambi concluded, Folks with arthritis are looking for http://www.024zone.com/ [pain relief]. That is the bottom line. Our pain relief products have a ten year track record for providing pain relief to people all over the world. Our products are natural and safe, and they work.

About Swiss Medica Inc.
Swiss Medica commercializes proprietary bioscience products that relieve chronic ailments, such as http://www.swissmedica.com [arthritis]. We increase our market share through focused distribution strategies in multiple sales channels. Swiss Medicas mission is to be a world leader in the commercialization of life enhancing bioscience products that improve quality of lives. Please visit our websites at www.swissmedica.com and www.O24zone.com.

Forward-looking statements in this news release are made pursuant to the "Safe Harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close transactions being contemplated, risks related to international sales and potential foreign currency exchange fluctuations, continued acceptance of Swiss Medicas products, increased levels of competition, technological changes, dependence on intellectual property rights and other risks detailed from time to time in Swiss Medicas periodic reports filed with the United States Securities and Exchange Commission and other regulatory authorities.

Investor Relations:
Current Capital
Robert Kennedy, President
877-859-5200

# # #